Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Poniard Pharmaceuticals has reported safety and efficacy data from a dose-escalating Phase I study of picoplatin in combination with full-dose docetaxel with prednisone as a first-line treatment for metastatic hormone refractory prostate cancer.
Subscribe to our email newsletter
In this study, 33 patients were treated with one of four doses (60, 80, 100 or 120mg/m squared) of picoplatin, as well as either 60mg/m squared or 75mg/m squared (full-dose) docetaxel plus 5mg prednisone twice daily. Nine patients received 120mg/m squared picoplatin and 75mg/m squared docetaxel every 21 days plus 5mg prednisone twice daily. This dose, which is also the dose currently under study in the Phase II trial, was well tolerated.
Jerry McMahon, chairman and CEO of Poniard, said: “The data we have generated with picoplatin in prostate cancer indicate a PSA (prostate specific antigen) response of 65% which suggests an improvement compared to docetaxel therapy alone. In addition, the tolerability of picoplatin with full-dose docetaxel supports our ongoing Phase II study that we believe will confirm and extend these initial findings.”